 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...195196197198199200201202203204205...208209» |
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Enrollment change, Metastases: A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ?III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction (clinicaltrials.gov) - Jan 17, 2018
P2, N=48, Recruiting, Sponsor: Hebei Medical University
Not yet recruiting --> Recruiting | N=40 --> 48
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date, Trial primary completion date: Apatinib for Resectable Colorectal Cancer (clinicaltrials.gov) - Jan 12, 2018
P=N/A, N=80, Recruiting, Sponsor: Nanchong Central Hospital
Not yet recruiting --> Recruiting | N=40 --> 48 Initiation date: Aug 2017 --> Mar 2018 | Trial primary completion date: Apr 2022 --> Mar 2021
- | AiTan (rivoceranib) / Elevar Therapeutics
New trial: Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 11, 2018
P=N/A, N=248, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- ||| SHR-A1403 / Jiangsu Hengrui Pharma
New P1 trial: Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jan 11, 2018
P1, N=100, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 10, 2018
P2, N=120, Recruiting, Sponsor: Henan Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P1 trial, Tumor mutational burden: LSK-AM107: A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Jan 10, 2018
P1, N=30, Recruiting, Sponsor: LSK BioPartners Inc.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial, PD(L)-1 Biomarker, IO biomarker: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) - Jan 9, 2018
P1/2, N=70, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Combination therapy, Metastases: A Study of Apatinib Treatment in for Advanced Ovarian Cancer (clinicaltrials.gov) - Jan 8, 2018
P2, N=34, Recruiting, Sponsor: The People's Hospital of Leshan
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor (clinicaltrials.gov) - Jan 8, 2018
P1, N=28, Not yet recruiting, Sponsor: SYZ Cell Therapy Co..
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer (clinicaltrials.gov) - Jan 4, 2018
P=N/A, N=50, Recruiting, Sponsor: Wuhan University
Initiation date: Aug 2017 --> Mar 2018 | Trial primary completion date: Apr 2022 --> Mar 2021 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / Elevar Therapeutics
New P2 trial: A Study of Apatinib in Recurrent or Recurrent High-grade Glioma (clinicaltrials.gov) - Jan 3, 2018
P2, N=30, Not yet recruiting, Sponsor: West China Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial initiation date, Trial primary completion date: APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) - Jan 3, 2018
P2, N=37, Recruiting, Sponsor: Peking University People's Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2019 --> Sep 2019
- ||||| AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2018
P2, N=60, Recruiting, Sponsor: Henan Cancer Hospital
- ||||| AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC (clinicaltrials.gov) - Jan 3, 2018
P2, N=144, Not yet recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
- ||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Phase classification: A Study to Evaluate SHR-1210 in Subjects With Advanced HCC (clinicaltrials.gov) - Dec 27, 2017
P2, N=220, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2019 --> Sep 2019 Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P2
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma (clinicaltrials.gov) - Dec 26, 2017
P2, N=20, Recruiting, Sponsor: Henan Cancer Hospital
- ||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment closed: PHENIX: A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Dec 20, 2017
P3, N=350, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P2 Recruiting --> Active, not recruiting
- |||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open: Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (clinicaltrials.gov) - Dec 20, 2017
P3, N=240, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P4 trial: Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Dec 19, 2017
P4, N=100, Recruiting, Sponsor: Zhengzhou University
- ||||| AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Real-world evidence: Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 18, 2017
P2, N=100, Not yet recruiting, Sponsor: Sichuan Provincial People's Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New trial: Apatinib in Advanced Non-squamous?NSCLC (clinicaltrials.gov) - Dec 18, 2017
P=N/A, N=100, Recruiting, Sponsor: Jian Fang
- ||||| AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma (clinicaltrials.gov) - Dec 18, 2017
P2, N=120, Recruiting, Sponsor: Henan Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date, Trial primary completion date: Phase I Study of the Combination of Apatinib and POF (clinicaltrials.gov) - Dec 15, 2017
P1, N=9, Not yet recruiting, Sponsor: Fujian Cancer Hospital
Not yet recruiting --> Recruiting Initiation date: Aug 2017 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Dec 2018
- |||| otesaconazole (VT-1161) / Mycovia Pharma
Trial completion, Enrollment change, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail (clinicaltrials.gov) - Dec 14, 2017
P2, N=259, Completed, Sponsor: Viamet
Initiation date: Aug 2017 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Dec 2018 Active, not recruiting --> Completed | N=200 --> 259 | Trial primary completion date: Jul 2016 --> Oct 2016
- |||| otesaconazole (VT-1161) / Mycovia Pharma
Trial completion, Enrollment change, Trial primary completion date: A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Dec 14, 2017
P2, N=254, Completed, Sponsor: Viamet
Active, not recruiting --> Completed | N=200 --> 259 | Trial primary completion date: Jul 2016 --> Oct 2016 Active, not recruiting --> Completed | N=200 --> 254 | Trial primary completion date: Jul 2016 --> Nov 2016
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date: LANCET: Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 12, 2017
P2, N=60, Not yet recruiting, Sponsor: Guangdong General Hospital
Active, not recruiting --> Completed | N=200 --> 254 | Trial primary completion date: Jul 2016 --> Nov 2016 Initiation date: Aug 2017 --> Jan 2018
- | AiTan (rivoceranib) / HLB Bio Group
Trial primary completion date: Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy (clinicaltrials.gov) - Dec 7, 2017
P2, N=36, Recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
Initiation date: Aug 2017 --> Jan 2018 Trial primary completion date: Mar 2018 --> Dec 2018
- | AiTan (rivoceranib) / HLB Bio Group
New P3 trial: mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer (clinicaltrials.gov) - Dec 7, 2017
P3, N=300, Recruiting, Sponsor: Huashan Hospital
- ||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2017
P2, N=97, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) - Dec 2, 2017
P2, N=37, Not yet recruiting, Sponsor: Peking University People's Hospital
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 30, 2017
P2, N=60, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial primary completion date: Mar 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer (clinicaltrials.gov) - Nov 29, 2017
P2, N=44, Not yet recruiting, Sponsor: Shanxi Province Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer (clinicaltrials.gov) - Nov 28, 2017
P2, N=20, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P3 trial, Metastases: XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma (clinicaltrials.gov) - Nov 28, 2017
P3, N=456, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New trial: HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer (clinicaltrials.gov) - Nov 22, 2017
P=N/A, N=50, Not yet recruiting, Sponsor: Wuhan University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ?III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction (clinicaltrials.gov) - Nov 22, 2017
P2, N=40, Not yet recruiting, Sponsor: Hebei Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer (clinicaltrials.gov) - Nov 20, 2017
P2, N=20, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial: A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Nov 17, 2017
P2, N=30, Recruiting, Sponsor: Chinese PLA General Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs (clinicaltrials.gov) - Nov 17, 2017
P1/2, N=30, Recruiting, Sponsor: Chinese PLA General Hospital
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Trial completion: A Study of SHR-1314 in Healthy Subjects (clinicaltrials.gov) - Nov 14, 2017
P1, N=40, Completed, Sponsor: Atridia Pty Ltd.
Active, not recruiting --> Recruiting Recruiting --> Completed
- HTI-1090 / Jiangsu Hengrui Pharma
Enrollment open: A Trial of HTI-1090 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 14, 2017
P1, N=30, Recruiting, Sponsor: Atridia Pty Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date: XHZL: Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 8, 2017
P2, N=50, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
Not yet recruiting --> Recruiting Initiation date: Aug 2017 --> Dec 2017
- | AiTan (rivoceranib) / HLB Bio Group
New trial, Real-world evidence, Real-world: The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=1000, Recruiting, Sponsor: The First Affiliated Hospital of Anhui Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: HYF001: Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer (clinicaltrials.gov) - Nov 7, 2017
P2, N=60, Recruiting, Sponsor: Anhui Provincial Hospital
- ||||| NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
New P2 trial: Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (clinicaltrials.gov) - Nov 6, 2017
P2, N=300, Not yet recruiting, Sponsor: Novaliq GmbH
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P1 trial: Drug-drug Interaction Between Simvastatin and SHR3824 (clinicaltrials.gov) - Nov 1, 2017
P1, N=12, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Enrollment open: ESSENCE: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (clinicaltrials.gov) - Oct 30, 2017
P2b, N=316, Recruiting, Sponsor: Novaliq GmbH
Initiation date: Aug 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 25, 2017
P2, N=80, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer (clinicaltrials.gov) - Oct 19, 2017
P2, N=48, Recruiting, Sponsor: Zhou Fuxiang
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Enrollment open, Enrollment change: Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level (clinicaltrials.gov) - Oct 17, 2017
P1, N=24, Recruiting, Sponsor: Atridia Pty Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=32 --> 24